trial

Improving Negative Symptoms of Psychosis In Real-world Environments

NCTId NCT02170051
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 64 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2018-09-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
64 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2014-07-01
Primary completion
2018-09-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
CBSST-CCTGoal focused supportive contact

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

2
Elizabeth W. Twamley, PhDPrincipal Investigator
Eric L. Granholm, PhDPrincipal Investigator

Sites

1 total
La Jolla, United States

Facts & assertions

4 sourced
Enrollment
64
Phase
NA
Primary Completion Date
2018-09-03
Status
COMPLETED
relationships
The graph out of here
drug
CBSST-CCT
drug
Goal focused supportive contact
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Elizabeth W. Twamley, PhD
person
Eric L. Granholm, PhD
person